CorMedix (NASDAQ:CRMD) Given Outperform Rating at Oppenheimer

CorMedix (NASDAQ:CRMD)‘s stock had its “outperform” rating restated by equities research analysts at Oppenheimer in a report released on Friday, Benzinga reports. They presently have a $13.00 target price on the stock, down from their previous target price of $15.00. Oppenheimer‘s price objective would indicate a potential upside of 167.77% from the company’s previous close.

A number of other equities research analysts have also issued reports on CRMD. Needham & Company LLC upped their target price on shares of CorMedix from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday. UBS Group set a $19.00 target price on CorMedix in a research report on Tuesday. Royal Bank Of Canada raised their target price on CorMedix from $14.00 to $15.00 and gave the company an “outperform” rating in a report on Tuesday. Weiss Ratings downgraded CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday. Finally, Citigroup reiterated a “market outperform” rating on shares of CorMedix in a research note on Tuesday. Eight investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, CorMedix has a consensus rating of “Moderate Buy” and a consensus price target of $15.22.

CorMedix Stock Performance

Shares of NASDAQ CRMD traded up $0.01 during trading on Friday, hitting $4.86. The company had a trading volume of 477,683 shares, compared to its average volume of 1,614,163. CorMedix has a 12 month low of $4.72 and a 12 month high of $13.02. The firm has a market capitalization of $378.40 million, a P/E ratio of 2.27, a price-to-earnings-growth ratio of 0.99 and a beta of 1.48. The stock has a 50 day simple moving average of $7.25 and a 200 day simple moving average of $7.58. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.36 and a current ratio of 2.56.

CorMedix (NASDAQ:CRMD) last announced its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). CorMedix had a net margin of 40.49% and a return on equity of 40.52%. The business had revenue of $54.52 million for the quarter, compared to analysts’ expectations of $51.76 million. As a group, analysts anticipate that CorMedix will post 0.54 earnings per share for the current year.

Institutional Trading of CorMedix

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Advisors Asset Management Inc. purchased a new position in CorMedix in the third quarter valued at about $26,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of CorMedix in the 3rd quarter worth about $31,000. Kestra Advisory Services LLC grew its stake in CorMedix by 142.9% in the 1st quarter. Kestra Advisory Services LLC now owns 10,200 shares of the company’s stock valued at $69,000 after acquiring an additional 6,000 shares during the last quarter. Quantbot Technologies LP purchased a new position in CorMedix during the 2nd quarter valued at about $85,000. Finally, Allworth Financial LP purchased a new position in CorMedix during the 2nd quarter valued at about $88,000. Institutional investors and hedge funds own 34.18% of the company’s stock.

Key Stories Impacting CorMedix

These are some of the CRMD stories that stood out recently:

• Positive Sentiment: Q3 revenue was $54.5 million, topping analyst expectations of $51.76 million. The company reported adjusted EBITDA of $3.1 million and maintained its 2026 revenue outlook while narrowing its adjusted EBITDA guidance. CorMedix Q3 results and business update
• Positive Sentiment: Management expects the Heron assets to contribute $125 million–$150 million in pro forma 2027 revenue and targets $45 million–$60 million in annual synergies, offering a potential growth and cost-saving opportunity if realized. Heron revenue and synergy expectations
• Negative Sentiment: The company posted a $14.7 million net loss; reported EPS of a $0.19 loss missed the cited consensus estimate of a $0.12 loss. This contrasts with a Zacks report showing a smaller loss on its measure, underscoring differences in earnings calculations. Zacks Q3 earnings report

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.